VIPoma other imaging findings: Difference between revisions
Jump to navigation
Jump to search
Madhu Sigdel (talk | contribs) No edit summary |
m Bot: Removing from Primary care |
||
| (9 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{VIPoma}} | {{VIPoma}} | ||
{{CMG}}{{AE}}{{MSI}}{{PSD}} | {{CMG}}{{AE}}{{MSI}}{{PSD}}{{Homa}} | ||
==Overview== | ==Overview== | ||
Other imaging studies for VIPoma include [[somatostatin]] | Other [[imaging studies]] for VIPoma include [[somatostatin receptor]] [[Nuclear medicine|scintigraphy]] and [[Positron emission tomography|PET scan]] using radiolabeled [[somatostatin]] [[Analog (chemistry)|analogs]]. | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
[[Somatostatin]] | *[[Somatostatin receptor]] [[scintigraphy]] (Octreoscan) is used to localize the [[tumor]], which is usually [[metastasis|metastatic]] at presentation.<ref name="pmid24785507">{{cite journal| author=Abu-Zaid A, Azzam A, Abudan Z, Algouhi A, Almana H, Amin T| title=Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male. | journal=Hematol Oncol Stem Cell Ther | year= 2014 | volume= 7 | issue= 3 | pages= 109-15 | pmid=24785507 | doi=10.1016/j.hemonc.2014.03.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24785507 }}</ref><ref name="MüllerKupka2012">{{cite journal|last1=Müller|first1=Sven|last2=Kupka|first2=Susan|last3=Königsrainer|first3=Ingmar|last4=Northoff|first4=Hinnak|last5=Sotlar|first5=Karl|last6=Bock|first6=Thomas|last7=Kandolf|first7=Reinhard|last8=Traub|first8=Frank|last9=Königsrainer|first9=Alfred|last10=Zieker|first10=Derek|title=MSH2 and CXCR4 involvement in malignant VIPoma|journal=World Journal of Surgical Oncology|volume=10|issue=1|year=2012|pages=264|issn=1477-7819|doi=10.1186/1477-7819-10-264}}</ref><ref name="VirgoliniPatri2001">{{cite journal|last1=Virgolini|first1=I.|last2=Patri|first2=P.|last3=Novotny|first3=C.|last4=Traub|first4=T.|last5=Leimer|first5=M.|last6=Fuger|first6=B.|last7=Li|first7=S. R.|last8=Angelberger|first8=P.|last9=Raderer|first9=M.|last10=Wogritsch|first10=S.|last11=Kurtaran|first11=A.|last12=Kletter|first12=K.|last13=Dudczak|first13=R.|title=Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy|journal=Annals of Oncology|volume=12|issue=suppl 2|year=2001|pages=S41–S45|issn=0923-7534|doi=10.1093/annonc/12.suppl_2.S41}}</ref> | ||
< | *Functional [[Positron emission tomography|PET scan]] is also used to [[Diagnosis|diagnose]] [[somatostatin receptor]] positive [[neuroendocrine tumors]]. | ||
</ | * Nearly 80-90% of all VIPoma are [[Somatostatin receptor|somatostatin receptor positive]]. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Medicine]] | |||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category: | [[Category:Up-To-Date]] | ||
[[Category:Endocrinology]] | |||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category: | [[Category:Radiology]] | ||
Latest revision as of 00:40, 30 July 2020
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma other imaging findings On the Web |
|
American Roentgen Ray Society Images of VIPoma other imaging findings |
|
Risk calculators and risk factors for VIPoma other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]
Overview
Other imaging studies for VIPoma include somatostatin receptor scintigraphy and PET scan using radiolabeled somatostatin analogs.
Other Imaging Findings
- Somatostatin receptor scintigraphy (Octreoscan) is used to localize the tumor, which is usually metastatic at presentation.[1][2][3]
- Functional PET scan is also used to diagnose somatostatin receptor positive neuroendocrine tumors.
- Nearly 80-90% of all VIPoma are somatostatin receptor positive.
References
- ↑ Abu-Zaid A, Azzam A, Abudan Z, Algouhi A, Almana H, Amin T (2014). "Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male". Hematol Oncol Stem Cell Ther. 7 (3): 109–15. doi:10.1016/j.hemonc.2014.03.002. PMID 24785507.
- ↑ Müller, Sven; Kupka, Susan; Königsrainer, Ingmar; Northoff, Hinnak; Sotlar, Karl; Bock, Thomas; Kandolf, Reinhard; Traub, Frank; Königsrainer, Alfred; Zieker, Derek (2012). "MSH2 and CXCR4 involvement in malignant VIPoma". World Journal of Surgical Oncology. 10 (1): 264. doi:10.1186/1477-7819-10-264. ISSN 1477-7819.
- ↑ Virgolini, I.; Patri, P.; Novotny, C.; Traub, T.; Leimer, M.; Fuger, B.; Li, S. R.; Angelberger, P.; Raderer, M.; Wogritsch, S.; Kurtaran, A.; Kletter, K.; Dudczak, R. (2001). "Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy". Annals of Oncology. 12 (suppl 2): S41–S45. doi:10.1093/annonc/12.suppl_2.S41. ISSN 0923-7534.